Merck & Co Closing In On Seagen Acquisition

Deal Expected To Be Worth Around $38bn

 
• By Andrew McConaghie

Merck is closing in on the acquisition of the antibody drug conjugate specialists which would help the pharma giant consolidate its presence in oncology.

Merck & Co.
Merck has done lots of mid-sized M&A deals recently, but a Seagen buyout would be its biggest in years. • Source: Shutterstock

More from Business

More from Scrip